Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 561

1.

Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.

Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, Newman F, Polack FP, Randolph VB, Deatly A, Hackell J, Gruber W, Murphy BR, Collins PL.

J Infect Dis. 2005 Apr 1;191(7):1093-104.

2.

The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans.

Wright PF, Karron RA, Madhi SA, Treanor JJ, King JC, O'Shea A, Ikizler MR, Zhu Y, Collins PL, Cutland C, Randolph VB, Deatly AM, Hackell JG, Gruber WC, Murphy BR.

J Infect Dis. 2006 Feb 15;193(4):573-81.

3.

Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children.

Karron RA, Wright PF, Crowe JE Jr, Clements-Mann ML, Thompson J, Makhene M, Casey R, Murphy BR.

J Infect Dis. 1997 Dec;176(6):1428-36.

4.

Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.

Belshe RB, Newman FK, Anderson EL, Wright PF, Karron RA, Tollefson S, Henderson FW, Meissner HC, Madhi S, Roberton D, Marshall H, Loh R, Sly P, Murphy B, Tatem JM, Randolph V, Hackell J, Gruber W, Tsai TF.

J Infect Dis. 2004 Dec 15;190(12):2096-103.

5.

The future of respiratory syncytial virus vaccine development.

Polack FP, Karron RA.

Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S65-73.

PMID:
14730272
7.

Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates.

Jin H, Cheng X, Traina-Dorge VL, Park HJ, Zhou H, Soike K, Kemble G.

Vaccine. 2003 Sep 8;21(25-26):3647-52.

PMID:
12922094
8.

Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children.

Gomez M, Mufson MA, Dubovsky F, Knightly C, Zeng W, Losonsky G.

Pediatr Infect Dis J. 2009 Jul;28(7):655-8. doi: 10.1097/INF.0b013e318199c3b1.

PMID:
19483659
9.

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.

Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE Jr, Boyce TG, Halburnt LL, Reed GW, Whitehead SS, Anderson EL, Wittek AE, Casey R, Eichelberger M, Thumar B, Randolph VB, Udem SA, Chanock RM, Murphy BR.

J Infect Dis. 2000 Nov;182(5):1331-42.

12.

A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.

Karron RA, Belshe RB, Wright PF, Thumar B, Burns B, Newman F, Cannon JC, Thompson J, Tsai T, Paschalis M, Wu SL, Mitcho Y, Hackell J, Murphy BR, Tatem JM.

Pediatr Infect Dis J. 2003 May;22(5):394-405.

PMID:
12792378
15.
16.

Challenges in developing a pediatric RSV vaccine.

Schickli JH, Dubovsky F, Tang RS.

Hum Vaccin. 2009 Sep;5(9):582-91. Review.

PMID:
19556888
17.

Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics.

Collins PL, Whitehead SS, Bukreyev A, Fearns R, Teng MN, Juhasz K, Chanock RM, Murphy BR.

Adv Virus Res. 1999;54:423-51. Review.

PMID:
10547682
18.

Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children.

Wright PF, Belshe RB, Kim HW, Van Voris LP, Chanock RM.

Infect Immun. 1982 Jul;37(1):397-400.

19.
20.

Carriers for the delivery of a vaccine against respiratory syncytial virus.

Cranage M, Taylor G.

Expert Opin Biol Ther. 2005 Jul;5(7):939-52. Review.

PMID:
16018739
Items per page

Supplemental Content

Support Center